New covid-19 sa-mrna results from csl and arcturus therapeutics demonstrate longer duration of immunity compared to conventional covid-19 mrna vaccine booster

Study conducted by meiji seika pharma in japan short communication follows previously published data in the lancet infectious diseases demonstrating immunological  non-inferiority to wuhan strain and superior immunogenicity to omicron ba.4/5 variant compared to first-generation mrna vaccine booster  ne w data demonstrates continuous advantage of sa-mrna over conventional mrna vaccine in terms of duration of immune response these results follow approval of the world's first sa-mrna covid-19 vaccine for adults by japan ministry of health, labor and welfare in november 2023 king of prussia, pa. and san diego , feb. 5, 2024 /prnewswire/ -- global biotechnology leader csl (asx:csl; usotc:cslly) and arcturus therapeutics (nasdaq: arct) today announced the results of a follow-up analysis of a phase 3 study evaluating a booster dose of arct-154 , the world's first approved self-amplifying messenger rna (sa-mrna) covid-19 vaccine, compared to a conventional mrna covid-19 vaccine.
ARCT Ratings Summary
ARCT Quant Ranking